Allermi
Signal active
Organization
Contact Information
Overview
Allermi is the first company to offer direct-to-consumer delivery of customized prescription allergy medications, designed and formulated by world-class allergists. We design and deliver relief by offering patients access to board-certified allergists, science-based medicine and customized prescription treatments.
About
Industries
Health Care, Wellness
Founded
2019
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Allermi headquartered in United States, North America, operates in the Health Care, Wellness sector. The company focuses on Health Care and has secured $114.0M in funding across 24 round(s). With a team of 1-10 employees, Allermi is actively contributing to advancements in Health Care. Their latest funding round, Series A - Allermi, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
0
Lead Investors
0
Total Funding Amount
$4.8M
Details
3
Allermi has raised a total of $4.8M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Seed | 1.3M | ||
| 2023 | Seed | 3.5M | ||
| 2024 | Early Stage Venture |
Investors
Allermi is funded by 7 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Allermi | - | FUNDING ROUND - Allermi | 3.5M |
| Nelstone Ventures | - | FUNDING ROUND - Nelstone Ventures | 3.5M |
| Allermi | - | FUNDING ROUND - Allermi | 3.5M |
| Shane Neman | - | FUNDING ROUND - Shane Neman | 3.5M |
Recent Activity
There is no recent news or activity for this profile.